Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03421327 · ClinicalTrials.gov registry record
Genetic Risk: Whether, When, and How to Tell Adolescents
A clinical trial of Huntington Disease and Hereditary Breast and Ovarian Cancer, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 85
- Enrollment target
- 1
- Study location
NCT03421327 is a study of Huntington Disease and Hereditary Breast and Ovarian Cancer that has completed, run by Johns Hopkins University. The registered enrollment target is 85 participants, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03421327, a study of Huntington Disease and Hereditary Breast and Ovarian Cancer, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 85 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for Huntington's Disease, parent/child pairs at risk for hereditary cancer, and genetic counselors.
Conditions Studied
Study Locations (1)
Maryland
- Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03421327
The ClinicalTrials.gov registry entry for NCT03421327 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 35 other Huntington Disease trials with a reported enrollment target (87% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Huntington Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03421327 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03421327 about?
NCT03421327 is a clinical study titled "Genetic Risk: Whether, When, and How to Tell Adolescents". This study is being conducted to learn more about family communication of genetic risk information. Semi-structured interviews lasting up to one hour will be conducted with three populations: parent/child pairs at risk for Huntington's Disease, parent/child pairs at risk for hereditary cancer, and g...
What is the current status of trial NCT03421327?
This trial is currently completed. The enrollment target is 85 participants. The study started on 2017-09-01. Estimated completion is 2018-12-31.
What conditions does trial NCT03421327 study?
This clinical trial studies the following conditions: Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome.
Who is sponsoring clinical trial NCT03421327?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03421327 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.